Synergistic composition comprising propolis and carnosic acid for use in the prevention and treatment of candidiasis. The invention relates to a synergistic composition comprising propolis that comprises polyphenols at a concentration between 70 and 90% by weight of propolis and carnosic acid, for use in the prevention and treatment of candidiasis in humans and/or animals. The invention also relates to a synergistic pharmaceutical and/or veterinary composition and a synergistic food product.

The present invention relates to a biotechnological process for the production of a fermented pollen comprising the inoculation of pollen with at least one lactic bacterium of the species Lactobacillus kunkeei and the fermentation of the pollen inoculated with the lactic bacterium. The fermented pollen obtained has nutritional and organoleptic properties similar to bee bread naturally produced inside the honeycomb of the beehive and finds application in the food and nutraceutical field.

The present invention relates to a biotechnological process for the production of a fermented pollen comprising the inoculation of pollen with at least one lactic bacterium of the species Lactobacillus kunkeei and the fermentation of the pollen inoculated with the lactic bacterium. The fermented pollen obtained has nutritional and organoleptic properties similar to bee bread naturally produced inside the honeycomb of the beehive and finds application in the food and nutraceutical field.

A novel standardized liquid propolis extract and pharmaceutical formulation based on said extract, as well as their manufacturing methods and uses, are provided. The liquid extract is produced by extraction of crude propolis with an extraction solvent based on a mixture of PEG 200-600 (96.5-99.9% w/w) and lecithins (0.1-3.5% w/w). The extract is characterized with standardized content of p-coumaric acid (1), trans-ferulic acid (2), caffeic acid (3), and CAPE (4). It is used as an active ingredient in manufacturing of pharmaceutical, cosmetic, veterinary, agrochemical or functional food products. The pharmaceutical formulation according to the invention consists of 5-95% w/w of the said propolis extract and up to 100% excipients required for preparation of various dosage forms. It is used for treatment of diseases and conditions in humans and animals such as: inflammatory diseases, bacterial and fungal infections, viral, autoimmune and cancer diseases, and for the treatment of burns and wound healing.

A novel standardized liquid propolis extract and pharmaceutical formulation based on said extract, as well as their manufacturing methods and uses, are provided. The liquid extract is produced by extraction of crude propolis with an extraction solvent based on a mixture of PEG 200-600 (96.5-99.9% w/w) and lecithins (0.1-3.5% w/w). The extract is characterized with standardized content of p-coumaric acid (1), trans-ferulic acid (2), caffeic acid (3), and CAPE (4). It is used as an active ingredient in manufacturing of pharmaceutical, cosmetic, veterinary, agrochemical or functional food products. The pharmaceutical formulation according to the invention consists of 5-95% w/w of the said propolis extract and up to 100% excipients required for preparation of various dosage forms. It is used for treatment of diseases and conditions in humans and animals such as: inflammatory diseases, bacterial and fungal infections, viral, autoimmune and cancer diseases, and for the treatment of burns and wound healing.